Evidence map›Paper›PMID 26223646›Full record

ArticleJournal of virology2015

Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif.

Matthew W Breed, Samra E Elser, Workineh Torben, Andrea P O Jordan, Pyone P Aye, Cecily Midkiff, Faith Schiro, Chie Sugimoto, Xavier Alvarez-Hernandez, Robert V Blair and 16 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. The Role of Integrin αCurrent HIV/AIDS reports · 2018
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 2 countries.

Matthew W BreedTulane National Primate Research Center, Covington, Louisiana, USA.
Samra E ElserPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Workineh TorbenTulane National Primate Research Center, Covington, Louisiana, USA.
Andrea P O JordanPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Pyone P AyeTulane National Primate Research Center, Covington, Louisiana, USA.
Cecily MidkiffTulane National Primate Research Center, Covington, Louisiana, USA.
Faith SchiroTulane National Primate Research Center, Covington, Louisiana, USA.
Chie SugimotoTulane National Primate Research Center, Covington, Louisiana, USA.
Xavier Alvarez-HernandezTulane National Primate Research Center, Covington, Louisiana, USA.
Robert V BlairTulane National Primate Research Center, Covington, Louisiana, USA.
Anoma SomasunderamBaylor College of Medicine, Houston, Texas, USA.
Netanya S UtayBaylor College of Medicine, Houston, Texas, USA.
Marcelo J KurodaTulane National Primate Research Center, Covington, Louisiana, USA.
Bapi PaharTulane National Primate Research Center, Covington, Louisiana, USA.
Roger W WisemanUniversity of Wisconsin National Primate Research Center, Madison, Wisconsin, USA.
David H O'ConnorUniversity of Wisconsin National Primate Research Center, Madison, Wisconsin, USA.
Celia C LaBrancheDuke University Medical Center, Durham, North Carolina, USA.
David C MontefioriDuke University Medical Center, Durham, North Carolina, USA.
Mark MarshMRC Laboratory for Molecular Cell Biology, University College, London, United Kingdom.
Yuan LiAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Michael PiatakAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Jeffrey D LifsonAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Patricia N FultzUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.
Andrew A LacknerTulane National Primate Research Center, Covington, Louisiana, USA.
James A HoxiePerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA hoxie@mail.med.upenn.edu.ORCID http://orcid.org/0000-0002-6257-4902
Tulane University · USLeidos (United States) · USUniversity of Pennsylvania · USBaylor College of Medicine · USDuke Medical Center · USUniversity of Wisconsin–Madison · USMRC Laboratory for Molecular Cell Biology · GBUniversity of Alabama at Birmingham · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
TRAINING IN HIV PATHOGENESIST32AI007632 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Frederic D Bushman, James L. Riley · 2000 to 2026
$10.6M
Macrophages in the pathogenesis of AIDSR01AI097059 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KURODA, MARCELO J · 2012 to 2016
$4.0M
VMD-PhD Training in Infectious Disease-Related ResearchT32AI070077 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Michael Lee Atchison · 2008 to 2026
$3.5M
Research Training in Experimental Medicine and PathologyT32OD011124 · OD · TULANE UNIVERSITY OF LOUISIANA · PI BLAIR, ROBERT, RAPPAPORT, JAY · 2012 to 2019
$2.7M
Leica TCS SP8 Confocal Microscope SystemS10OD019964 · OD · TULANE UNIVERSITY OF LOUISIANA · PI LACKNER, ANDREW A · 2015 to 2015
$478k
Medical Research Council MC_UU_12018/1Medical Research Council MR/K015826/1NIAID NIH HHS P30 AI045008NIAID NIH HHS R01 AI097059NIAID NIH HHS T32 AI007632NIAID NIH HHS T32 AI070077NIH HHS P51 OD011104NIH HHS S10 OD019964NIH HHS T32 OD011124
6 · The paper itself

Abstract

unlabelledDeletion of Gly-720 and Tyr-721 from a highly conserved GYxxØ trafficking signal in the SIVmac239 envelope glycoprotein cytoplasmic domain, producing a virus termed ΔGY, leads to a striking perturbation in pathogenesis in rhesus macaques (Macaca mulatta). Infected macaques develop immune activation and progress to AIDS, but with only limited and transient infection of intestinal CD4(+) T cells and an absence of microbial translocation. Here we evaluated ΔGY in pig-tailed macaques (Macaca nemestrina), a species in which SIVmac239 infection typically leads to increased immune activation and more rapid progression to AIDS than in rhesus macaques. In pig-tailed macaques, ΔGY also replicated acutely to high peak plasma RNA levels identical to those for SIVmac239 and caused only transient infection of CD4(+) T cells in the gut lamina propria and no microbial translocation. However, in marked contrast to rhesus macaques, 19 of 21 pig-tailed macaques controlled ΔGY replication with plasma viral loads of <15 to 50 RNA copies/ml. CD4(+) T cells were preserved in blood and gut for up to 100 weeks with no immune activation or disease progression. Robust antiviral CD4(+) T cell responses were seen, particularly in the gut. Anti-CD8 antibody depletion demonstrated CD8(+) cellular control of viral replication. Two pig-tailed macaques progressed to disease with persisting viremia and possible compensatory mutations in the cytoplasmic tail. These studies demonstrate a marked perturbation in pathogenesis caused by ΔGY's ablation of the GYxxØ trafficking motif and reveal, paradoxically, that viral control is enhanced in a macaque species typically predisposed to more pathogenic manifestations of simian immunodeficiency virus (SIV) infection. IMPORTANCE: The pathogenesis of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) reflects a balance between viral replication, host innate and adaptive antiviral immune responses, and sustained immune activation that in humans and Asian macaques is associated with persistent viremia, immune escape, and AIDS. Among nonhuman primates, pig-tailed macaques following SIV infection are predisposed to more rapid disease progression than are rhesus macaques. Here, we show that disruption of a conserved tyrosine-based cellular trafficking motif in the viral transmembrane envelope glycoprotein cytoplasmic tail leads in pig-tailed macaques to a unique phenotype in which high levels of acute viral replication are followed by elite control, robust cellular responses in mucosal tissues, and no disease. Paradoxically, control of this virus in rhesus macaques is only partial, and progression to AIDS occurs. This novel model should provide a powerful tool to help identify host-specific determinants for viral control with potential relevance for vaccine development.

Indexed as

Amino Acid MotifsImmunity, MucosalSequence DeletionAnimalsCD4-Positive T-LymphocytesDisease ProgressionFemaleGene ExpressionIntestinesMacaca mulattaMacaca nemestrinaMaleMolecular Sequence DataMucous MembraneProtein Sorting SignalsProtein Structure, TertiaryProtein Sorting SignalsViral Envelope Proteins

Identifiers

PMID26223646
PMCPMC4580161
OpenAlexW2185126317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.